Figure 4
From: Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses
Prophylactic immunization with Mage-a1-Hsp70 fusion protein protects mice against B16-Mage-a1 tumor cell challenge. C57BL/6 mice were immunized with purified GST, Hsp70, Mage-a1, Mage-a1-Hsp70 fusion protein or Mage-a1 + Hsp70 and then administered a booster immunization after one week. A week after the booster, the mice were challenged with 1 × 105 B16-Mage-a1 melanoma cells. A. The tumor free status of mice was recorded as the percentage of mice remaining tumor-free every three days after tumor challenge. B. Tumor growth was recorded as the mean tumor volume (in mm3). Error bars depict the SE, n = 8 mice/group. Statistical analysis by two-way ANOVA revealed that from days 31 to 37 vaccination with Mage-a1-Hsp70 significantly delayed tumor growth in the B16-Mage-a1 tumor model compared to vaccination with Mage-a1 or Mage-a1 + Hsp70 (* p < 0.01).